Physician profile
Michelle Lynn Pendleton
NPI 1134596802
$1,912.68
in general payments reported to CMS, 2019-2025
23 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $126 · 2023: $348 · 2024: $479 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $368.03 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $335.10 | 2021-2025 | |
| Lilly USA, LLC | $326.48 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $112.75 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.39 | 2023-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $93.79 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $76.77 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $63.94 | 2023-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $52.98 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $51.64 | 2023-2025 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $43.92 | 2021 | |
| Abbott Laboratories | $40.94 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $38.63 | 2025 | Capvaxive, Gardasil 9, Enflonsia |
| Idorsia Pharmaceuticals US INC | $31.97 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $29.62 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $23.82 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.94 | 2025 | Jardiance |
| Cvrx, INC. | $21.25 | 2024 | Barostim Neo System |
| Medtronic, INC. | $17.59 | 2023 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $13.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.32 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.83 | 2022 | |
| Boston Scientific Corporation | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.